$MOH

Molina Healthcare Reports Third Quarter 2026 Financial Results

MOLINA HEALTHCARE, INC. (MOH) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release Investor Contact: Jeffrey Geyer, Jeffrey.Geyer@molinahealthcare.com , 305-317-3012 Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com , 562-542-1845 Molina Healthcare Reports Third Quarter 2026 Financial Results Reaffirms Full Year 2026 Earnings G

Original reporting
Published Oct 21, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MOH
Bearish
high confidence
Mentioned
$MOH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MOHBearishHigh
01

Why it matters

The earnings miss and modest guidance reaffirmation are likely to generate short‑term price pressure, while the company's large scale keeps the news material for traders.

02

Market read

Molina Healthcare's earnings release is a primary corporate event with significant market relevance for the U.S. health‑insurance sector.

03

What to watch

Rate updates for 2027 and a potential turn in Medicaid margins could support future earnings recovery.

Relevance 7/10Novelty 9/10Timing: after‑hours release on Oct 21, 2026

Background

The filing is a standard SEC Form 8‑K earnings release for Q3 2026, providing the first public disclosure of the quarter's financials.

Company-level read

Ticker impact

$MOHBearishHigh confidence
Context

Molina Healthcare (MOH) reported Q3 2026 GAAP EPS of $0.73 and adjusted EPS of $0.89, reaffirming full‑year 2026 earnings guidance.

Expected impact

likely downside pressure as investors digest lower earnings and modest guidance reaffirmation

Evidence & confidence

The company posted a 52% YoY drop in GAAP net income and a 53% drop in adjusted earnings, while only reaffirming guidance, which typically limits upside and may trigger short‑term selling.

Market effects

Results highlight pressure on Medicaid/Medicare margins, signaling potential challenges for other health‑insurer peers.

U.S. health‑insurance sector may see modest weakness in the short term.

Limited; impact confined to U.S. managed‑care market.

Counterpoint

The reaffirmed guidance could be a floor, and any upside may emerge if cost‑containment improves faster than expected.

Key entities

  • Joseph Zubretsky

    President and CEO of Molina Healthcare, quoted in the release.

Related articles

$MOHHighAI 8/10

Molina: Q3 Earnings Snapshot

Molina Healthcare (MOH) reported Q3 net income of $38M, or 73 cents per share, beating analyst estimates of 72 cents. Revenue was $11.08B, exceeding expectations of $10.93B. The company forecasts full-year earnings of $5.25 per share and revenue of $42B.

$MOHHighAI 8/10

Molina Healthcare’s (NYSE:MOH) Q3 2026 sales top estimates

Molina Healthcare (MOH) reported Q3 2026 revenue of $11.08B, down 3.4% YoY but exceeding estimates by 2%. Adjusted operating margin was 1.2%, and EPS was $0.89, down from last year but beating estimates. Analysts project 9% revenue growth and 311% EPS growth over the next 12 months. The stock fell 4.1% post-results.

$MOHHighAI 8/10

Molina Healthcare falls 4% on challenging environment, despite beating third quarter estimates

Molina Healthcare (NYSE:MOH) reported Q3 earnings of $0.89 per share, beating estimates by $0.10, with revenue at $11.08B, down 4% YoY. Shares fell 4.6% due to margin pressures and a challenging environment. The company reaffirmed its 2026 guidance of at least $5.25 per share. Membership and premium revenue declined due to lower Medicaid and Marketplace enrollment.

$MOHMedAI 8/10

Molina Healthcare, Inc. (MOH) Q3 EPS Down, Guidance Reaffirmed

Molina Healthcare (MOH) reported Q3 2026 GAAP EPS of $0.73 and adjusted EPS of $0.89, both down ~53% YoY, on $10.5B premium revenue (down 4%). The company reaffirmed 2026 guidance, including at least $2.38 GAAP EPS and $5.25 adjusted EPS. Management cited high medical costs as a pressure point but signaled potential stabilization.